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High-risk breast cancer comprises distinct tumor entities such as triple-negative breast cancer (TNBC) which is characterized by
lack of estrogen (ER) and progesterone (PR) and the HER2 receptor and breast malignancies which have spread to more than
three lymph nodes. For such patients, current (inter)national guidelines recommend anthracycline-based chemotherapy as the
standard of care, but not all patients do equally beneﬁt from such a chemotherapy. To further improve therapy decision-
making, predictive biomarkers are of high, so far unmet, medical need. In this respect, predictive biomarkers would permit
patient selection for a particular kind of chemotherapy and, by this, guide physicians to optimize the treatment plan for each
patient individually. Besides DNA mutations, DNA methylation as a patient selection marker has received increasing clinical
attention. For instance, signiﬁcant evidence has accumulated that methylation of the PITX2 (paired-like homeodomain
transcription factor 2) gene might serve as a novel predictive and prognostic biomarker, for a variety of cancer diseases. This
review highlights the current understanding of treatment modalities of high-risk breast cancer patients with a focus on
recommended treatment options, with special attention on the future clinical application of PITX2 as a predictive biomarker to
personalize breast cancer management.
1. Introduction
Breast cancer is the most common malignancy in women
with >464,000 new cases diagnosed in 2012 in Europe;
131,000 patients have died as a result of this disease [1]. In
the Western, one in eight women will experience breast can-
cer in her lifetime; every fourth is younger than 55 years of
age at the time of diagnosis [1]. Therapy decision in breast
cancer is mainly based on the established histopathological
parameters tumor size, lymph node status, histological type,
and histological grade. These factors do provide information
about the future clinical course of the disease (exempliﬁed as
disease-free survival, DFS, and overall survival, OS) of
patients not subjected to any systemic cancer therapy. Diﬀer-
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ent from that, predictive factors are biological markers,
which foretell the probability of a cancer patient to respond
to a speciﬁc anticancer therapy.
At present, these biomarkers include the steroid hormone
receptors ER and PR, the oncoprotein HER2, the urokinase-
type plasminogen activator (uPA), and the uPA inhibitor
PAI-1 [2] (ASCO: http://www.asco.org/practice-guidelines/
quality-guidelines/guidelines, AGO: http://www.ago-online.
de/en/guidelines-mamma/march-2016). According to the
opinion of the St. Gallen breast cancer classiﬁcation and
treatment panel, Ki-67, a cell proliferation marker, should
also be considered for therapy decision-making although no
standard protocols for this analysis were deﬁned and estab-
lished so far [3, 4].
By use of molecular classiﬁers and gene expression signa-
tures, invasive breast carcinomas can be further clinically cat-
egorized into at least four molecular subgroups (Table 1),
which are associated with diﬀerent clinical outcomes and
are the basis for choosing which kind of systemic therapy
should be applied, both for the adjuvant and the neoadjuvant
setting [4–8]. Patients in the luminal A/B groups are gener-
ally treated with endocrine therapy but, due to biological
heterogeneity in this group, quite often combined with che-
motherapy (Table 1). It is estimated that 20–40% of those
patients are treated cost- and side-eﬀect-rich with chemo-
therapy, although endocrine therapy would be suﬃcient.
Women with early-stage breast cancer presenting with
HER2+ tumors (HER2-type) are generally treated in the
adjuvant setting with the humanized antibody Herceptin®
plus additional chemotherapy. Since such targeted therapy
is not available for the TNBC patients, they are subject to sys-
temic adjuvant or neoadjuvant chemotherapy. Yet avoiding
not only overtreatment but also undertreatment of TNBC
patients has become a major treatment issue. Therefore,
TNBC-speciﬁc predictive biomarkers are urgently needed
to allow for the identiﬁcation of TNBC patients who will ben-
eﬁt from a particular systemic therapy. If not so, such TNBC
patients should be oﬀered alternative treatment plans to
achieve optimal cancer treatment, thereby avoiding poten-
tially toxic side eﬀects.
2. Definition of High-Risk Breast Cancer
Patients
Detailed information for risk stratiﬁcation of breast cancer
patients who would develop metastases is urgently needed
to provide eﬀective care early enough to ensure provision of
adequate anticancer treatment. In February 1998, the 6th
International Conference on “Adjuvant Therapy of Primary
Breast Cancer” was held in St. Gallen, Switzerland. In an
attempt to solve this problem, at this conference and subse-
quent St. Gallen meetings, guidelines and recommendations
were introduced in the scientiﬁc literature on how to select
the right breast cancer patient for adequate adjuvant systemic
treatment [9, 10]. According to the St. Gallen’s patient
stratiﬁcation criteria (Figures 1 and 2), patients with a low
risk to progress or to develop metastases (tumor size< 2 cm,
node-negative, or up to 3 lymph nodes aﬀected) will receive
endocrine therapy if ER and/or PR are expressed. High-risk
patients (node-positive with >3 lymph nodes involved,
tumor size≥ 2 cm) are subject to chemotherapy; the same
applies to TNBC patients. Intermediate-risk patients, which
are deﬁned by pN0-1 [4] or histological grade 2 [11], can
be allocated to the high-risk or low-risk group by applying
commercially available risk-assessment tests such as
MammaPrint® (Agendia), Endopredict® (Myriad Genetics),
or Oncotype DX® (Genomic Health) [4, 12].
TNBC tumors and tumors with >3 aﬀected lymph nodes
are both considered high-risk breast cancers. TNBC is char-
acterized by an increase in tumor size and high histological
grade with disease recurrence as early as 3–5 years after the
start of systemic cancer therapy [13, 14] and shorter survival
time following the ﬁrst metastatic event [1, 15–17]. Thus, the
5-year survival rate of TNBC patients is signiﬁcantly reduced
compared to other breast cancer subtypes.
Currently, there is no routinely available targeted ther-
apy established for TNBC patients and no predictive factors
have been introduced into the clinic which could provide
information about the response of a TNBC patient to a spe-
ciﬁc cancer therapy [2]. Primary breast cancer patients with
≤3 aﬀected lymph nodes but ER/PR negative status or HER2
positive are considered high-risk breast cancer patients as
well [18]. For those patients, anthracycline-based adjuvant
chemotherapy has become the standard of care. Several
studies showed that the addition of taxanes to this protocol
may further improve clinical outcome. Still, not all of
these high-risk patients will beneﬁt from such an intensiﬁed
therapy plan [19].
3. Treatment Options for High-Risk Breast
Cancer Patients
In addition to the established traditional histopathological
parameters (lymph node status, tumor size, histological type,
and histological grade), the decision who to treat and how to
treat is also based on whether ER/PR andHER2 are expressed
by the primary breast cancer tumor cells or not (Table 2). The
biomarkers uPA and PAI-1 are indicative factors to predict
response to adjuvant chemotherapy but in node-negative
breast cancer patients only [18, 25].
Originally, treatment in the neoadjuvant setting was
advised for the treatment of larger sometimes inoperable
breast cancers, but various considerations support the
implementation of neoadjuvant systemic chemotherapy in
operable breast cancer patients as well [4, 26]. Beneﬁts of
such a systemic therapy procedure are higher rates of
breast-conserving surgery and the opportunity to assess
early in vivo response to systemic treatment prior to primary
Table 1: Traditional classiﬁcation of breast cancer subgroups.
Classiﬁcation Expression Distribution (%)
Luminal A ER/PR+, HER2− ~65
Luminal B ER/PR+, HER2+/− ~15
HER2-type ER/PR−, HER2+ ~5
Triple-negative ER/PR−, HER2− ~15
According to [3, 5, 8] (http://ww5.komen.org/BreastCancer/SubtypesofBreast
Cancer.html).
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surgery. In addition, this approach might improve survival
of breast cancer patients by early elimination of occult
metastases. Neoadjuvant chemotherapy is particularly rec-
ommended for TNBC patients and patients aﬄicted with
HER2+ breast cancer [4]. Current adjuvant chemotherapy
standards for early breast cancer patients involve an
anthracycline plus taxane. These regimens generally do not
diﬀer for the neoadjuvant and the adjuvant settings [4].
Standard treatment for breast cancer patients with more
than three aﬀected lymph nodes is systemic therapy employ-
ing an anthracycline plus a taxane (Table 3), administered in
the adjuvant or neoadjuvant setting. In addition, anti-HER2
Low-risk: 10%1
(Neo)adjuvant therapy
ET: 52%
High-risk: 23%
CTX: 48%High-risk: 25%1
Intermediate risk: 65%1
Low-risk: 42%
Prognostic gene
expression test2
Figure 1: Clinicopathological risk stratiﬁcation of breast cancer patients according to St. Gallen criteria. 1Clinicopathological risk assessment
according to St. Gallen consensus panel [9, 20–24]. 2Endopredict®, OncotypeDX®. ET = endocrine therapy; CTX= chemotherapy.
PITX2 DNA methylation
has demonstrated
significant predictive value
Endocrine therapy
± chemotherapy
Chemotherapy
± endocrine therapy
± HER2-targeted therapy
Chemotherapy
± HER2-targeted therapy
Chemotherapy
± endocrine therapy
Chemotherapy
± endocrine therapy
Chemotherapy with
anthracycline + taxane
Triple-negative breast cancer
Any lymph node status
ER/PR-negative
HER2-negative
Any lymph node status
ER/PR-positive
HER2-negative
Affected lymph nodes: 1–3
ER/PR-positive
HER2-positive
Affected lymph nodes: 1–3
ER/PR-negative
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Lymph node-positive breast cancer pN1
Lymph node-positive breast cancer pN1
Lymph node-positive breast cancer pN1
Lymph node-positive breast cancer pN2/3
Affected lymph nodes: 1–3
Affected lymph nodes: >3
Lymph node-positive/negative breast
cancer, categorized high-risk by risk
factors or gene signature testing
(i)
(ii)
(iii)
(i)
(ii)
(iii)
(i)
(ii)
(iii)
(i)
(ii)
(iii)
(i)
(i)
Figure 2: Classiﬁcation of the high-risk breast cancer subtypes. PITX2 DNA methylation status can serve as a signiﬁcant predictive biomarker
for anthracycline-based chemotherapy in the two major high-risk breast cancer subtypes [44, 66].
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therapy forHER2+ tumors and/or endocrine therapy for ER/
PR+ tumors can be applied. Results of several trials address-
ing N+ high-risk breast cancer patients have shown that
dose-dense chemotherapy improves outcome compared to
standard interval chemotherapy [4]. Patients are treated by
adjuvant anthracycline-based chemotherapy; additional
treatment with adjuvant endocrine therapy will be adminis-
tered when tumor cells are ER/PR+. In patients with more
than three aﬀected lymph nodes, dose-dense and dose-
intensiﬁed epirubicin, paclitaxel, and cyclophosphamide led
not only to a signiﬁcant reduction in disease recurrence and
mortality but also to higher toxicities [4].
In general, in Germany, for the presurgical neoadju-
vant setting, TNBC patients are treated following the
AGO guidelines (http://www.ago-online.de/en/guidelines-
mamma/march-2016), which are characterized by core biop-
sies taken to allow histological diagnosis, followed by neoad-
juvant chemotherapy, primary surgery, and, if applicable,
further postsurgical chemotherapy. Anthracycline-based
chemotherapy is hereby the standard therapy option. For
high-risk N+ TNBC patients, a deﬁnite beneﬁt for the
patients was reported when anthracyclines were applied
in combination with taxanes [27]. In patients with highly
proliferating TNBC, in the adjuvant setting, anthracycline-
containing regimes improve disease-free and overall survival
when compared to treatment with CMF (combination of
cyclophosphamide, methotrexate, and 5-ﬂuorouracile [28]).
In TNBC patients, a favorable prognosis is predicted by
an eﬀective response to (neo)adjuvant chemotherapy, which
is deﬁned by high rate of pCR (pathological complete remis-
sion) which may serve as a surrogate endpoint for estimation
of long-term clinical outcomes of the patients [29]. Those
patients who will not achieve a pCR are at high risk of disease
recurrence within the next two years following surgery [29].
Until now, predictors of beneﬁt from anthracyclines, or a test
which predicts response to anthracycline-based treatment,
are not commercially available [28]. The addition of carbo-
platin or cisplatin can signiﬁcantly improve the rate of pCR
[13]. Platinum salts do eﬀect DNA cross-link strand breaks
and, thus, prevent DNA replication [7]. Staudacher et al.
[30] reported that overall survival was improved in metasta-
tic breast cancer patients responding to platinum-based
chemotherapy. Since 2014, results from several clinical trials
have indicated that addition of platinum salts to a neoadju-
vant anthracycline-taxane combination or sequence does
improve pCR [4].
4. Predictive Biomarkers in High-Risk Breast
Cancer
Breast cancer is a genetically and phenotypically very het-
erogeneous disease equipped with molecular diversity. It
may exhibit with distinct clinical appearance, regarding
varying response to treatment and clinical outcome. Conse-
quently, precise breast cancer stratiﬁcation for and forecast-
ing of eﬀectiveness of therapeutic modalities is a crucial
step toward a more beneﬁcial treatment design. For many
years, breast cancer patients have been stratiﬁed according
to their histopathological parameters such as histological
type and grade, tumor size, lymph node status, and the
ER/PR/HER2− status.
In recent years, signiﬁcant advances have been made
in characterizing the molecular characteristics of TNBC
[5, 8, 14]. This has led to the identiﬁcation of biomarkers
that potentially could be used for diagnostic purpose to assess
patient’s prognosis or as therapeutic targets. Irrespective of
the fact that today for TNBC there are no eﬀective targeted
therapies available. About one-third of the patients will
achieve pCR through standard-of-care anthracycline/taxane
chemotherapy; but how are these responders classiﬁed? So
far, the broad molecular heterogeneity of TNBC tumors has
hindered the discovery of eﬀective biomarkers to identify
such patients in order to tailor chemotherapy at an individual
level [13, 31, 32]. To further characterize TNBC on a molec-
ular level, various subtypes of TNBC have been proposed
[33] (Table 4).
Eighty to ninety percent of TNBCs belong to the BL
subtype. Despite some diﬀerences in the number of subtypes
or the classifying methods, regarding this issue, all of the
published studies suggested that TNBC consists of several
subtypes and thus does require subtype-speciﬁc therapy
based on its biological characteristics [34]. The clinical rele-
vance of the TNBC subtypes listed in Table 4, however, is
not yet deﬁned. Cancer biomarkers may be useful as diagnos-
tic, prognostic, or predictive indicators and may represent
potential targets for cancer therapy [34, 35]. Although there
are no clinically meaningful prognostic or predictive cancer
biomarkers available, a series of potential biomarkers have
been identiﬁed, for example, in the blood (VEGF), on the cell
surface (epithelial growth factor receptor 1 (EGFR)), and in
the cell nucleus (BRCA1, BRCA2) [32]. VEGF (vascular
epithelial growth factor receptor) causes proliferation of
endothelium cells and regulates vascular permeability and
migration of endothelial stem cells from the bone marrow
[34]. In TNBC patients, elevated VEGF levels were observed
to be associated with disease recurrence and survival proba-
bility [34], making VEGF a potential therapy target in TNBC.
Activation of EGFR causes transcription of genes thus
inducing cell proliferation, angiogenesis, metastatic spread,
and inhibition of apoptosis. EGFR was found to be overex-
pressed in many TNBC tumors and was shown to be a prog-
nostic factor for disease recurrence by univariate and
multivariate analysis [16, 29, 32]. Currently, tyrosine kinase
inhibitors (e.g., lapatinib and geﬁtinib) are applied in breast
cancer patients to block EGF-stimulated growth signal trans-
duction and that ofHER2 and the combination of these drugs
Table 2: Current therapeutic regimens for breast cancers contain.
(i) For patients with luminal A/B tumors (ER/PR+, HER2−):
endocrine therapy or chemotherapy followed by endocrine
therapy.
(ii) For patients with HER2+ tumors: chemotherapy plus
anti-HER2 therapy (e.g., with trastuzumab/pertuzumab) and,
if appropriate, endocrine therapy. The combination with
chemotherapy is currently recommended since by this therapy
a survival beneﬁt for the patients has been reported [4].
(iii) For TNBC patients: chemotherapy (anthracycline plus taxane)
(AGO guidelines 2016: http://www.ago-online.de/en/
guidelines-mamma/march-2016).
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with carboplatin or docetaxel synergistically may enhance
the treatment eﬀect in TNBC patients [29, 34, 36–38].
BRCA1 and BRCA2 germline mutations are more fre-
quent in TNBC than in other types of breast cancer and
aﬀect ~30% of TNBC patients [13, 39]. There is increas-
ing evidence that BRCA1 germline mutant breast cancers
present with above-average platinum sensitivity and
increased sensitivity to poly-ADP ribose polymerase (PARP)
inhibitors [13]. Germline mutations in the BRCA genes
(BRCA1, BRCA2) predispose individuals to develop several
kinds of cancer, including that of the breast [32]. Both
genes play a crucial role in DNA repair processes, and
the lack of functional BRCA1/2 proteins leads to loss of
repair of DNA double-strand breaks and subsequently
increases the risk of cancer. Mutated BRCA1-related breast
cancers share pathological features with TNBC, including
ER, PR, HER2, EGFR, TP53 expression, and genomic
instability [34, 40].
The link between TNBC and germline BRCA1 muta-
tions has led to the investigation of PARP inhibitors in
TNBC. PARPs are cell signaling enzymes which catalyze
the poly(ADP-ribosylation) of DNA binding proteins. The
main function is to act as a nick sensor for DNA damage,
which plays a vital role in DNA repair through the base
excision repair pathway: the base excision pathway fails when
PARP1 is inhibited. In BRCA1-deﬁcient cells, inhibition of
PARP1 leads to cell death through apoptosis [29]. Trials of
PARP inhibitors (e.g. iniparib, ocaparib, veliparib, talazo-
parib, and rucaparib) in TNBCs have shown improved rates
of response and progression-free survival [6, 15, 29, 41];
however, these studies are inconclusive [7].
Ki-67 is a marker for cell proliferation activity. In TNBC
patients, Ki-67 levels were related to tumor size and histolog-
ical grade, and it was associated with increased pCR when
responding to chemotherapy but with poor disease-free and
overall survival [34]. Ki-67 is one of the biomarkers which
is recommended to be included in breast cancer therapy
decision-making. However, so far, no standards for this
analysis are deﬁned [3].
In TNBC, the prevalence of the androgen receptor (AR) is
~10–20% [13, 42]. The LAR subtype of TNBC (Table 4) is
characterized by luminal gene expression, enriched for AR
expression and its target genes [33]. Clinically, individuals
with AR-TNBC have a higher likelihood of achieving a pCR
by treatment with neoadjuvant chemotherapy than those
with AR+ TNBC [42]. Next-generation sequencing activities
have identiﬁed further genes recurrently mutated in TNBC,
including TP53, PIK3CA, PTEN, RB1, RAS, and ERBB3,
but none of these genes have any predictive or prognostic
relevance [31].
According to the St. Gallen risk stratiﬁcation scheme
(Figure 1), the intermediate-risk group (pN0-1) can be
further classiﬁed into low- or high-risk by using multigene
expression assays, for example, Endopredict (Myriad
Genetics), Mammaprint (Agendia), OncotypeDX (Genomic
Health), and others. OncotypeDX delivers a 21-gene recur-
rence score, which gives information about the likelihood of
chemotherapy beneﬁt as well as the risk of disease recurrence
in early-stage breast cancer. This test is recommended for
breast cancer patients with tumors classiﬁed as N0/N+,
ER+ [12]. Mammaprint (70-gene signature) gives informa-
tion about a breast cancer patient’s risk for disease recurrence
and identiﬁes those patients that may safely forgo chemo-
therapy. Mammaprint is recommended for pN0 and pN+
breast cancer patients. Endopredict provides information
how to devise personalized treatment plans for breast cancer
patients. It detects the likelihood of late metastases (>5 years)
and can thus guide treatment decision for CTX and predicts
disease recurrence. This test is recommended for pN0-1,
ER+, HER2− breast cancer patients [4, 36].
Table 4: Subclassiﬁcation of TNBC based on gene expression analysis.
Characteristics
BL1 (basal-like 1) Increased expression of cell cycle and DNA repair genes
BL2 (basal-like 2) Increased expression of growth factor signaling and myoepithelial markers
M Increased expression of genes involved in epithelial-mesenchymal-like transition and growth factor pathways
MSL Decreased expression of genes involved in proliferation (mesenchymal stem cell-like)
IM Immune cell processes, expression of genes involved in cytokine signal immunomodulatory transduction pathway
LAR Luminal gene expression and androgen receptor signaling genes
According to Lehmann et al. [33] and Szekely et al. [13].
Table 3: Treatment options for high-risk breast cancer patients.
TNBC >3 lymph nodes aﬀected
Therapy: CTX Therapy: CTX, anti-HER2, or ET
(i) Anthracycline plus taxane
(ii) Neoadjuvant treatment (presurgical)
(iii) Adjuvant treatment (postsurgical)
(iv) Addition of carboplatin may improve pCR and
event-free survival
(i) Adjuvant treatment with anthracycline plus taxane
(ii) Anti-HER2 treatment if tumor HER2+, and/or endocrine
therapy if tumor ER/PR+
(iii) Regimens may also include platinum salts (cisplatin, carboplatin)
(iv) Dose-dense or dose-intensiﬁed CTX improves outcome in N+ patients
pCR: pathological complete response; CTX: chemotherapy; anthracyclines: doxorubicin, epirubicin; Taxanes: paclitaxel, docetaxel; N+: node-positive.
According to AGO guidelines (http://www.ago-online.de/en/guidelines-mamma/march-2016).
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All these multigene assays, however, deliver prognostic
information only but have no predictive value, also not for
TNBC patients [2]. In summary, none of these tests can
currently be recommended for predicting the response to
a speciﬁc form of chemotherapy or to be prognostic for
any kind of high-risk breast cancer patients [36]. In addition
to tumor size and nodal status, the ER/PR/HER2 status is cur-
rently the most important prognostic and predictive marker
in high-risk breast cancer. There is still a so far unmet need
for individualized systemic treatment of breast cancer to pre-
dict the necessity, eﬃcacy, and potentially toxic side eﬀects of
anticancer drugs and clinical outcome of breast cancer
patients under therapy. Thus, molecular tests, which can pre-
dict response or failure to a certain therapy, are highly needed
to provide a tailored therapy for the appropriate patient.
5. Epigenetics and Breast Cancer
The term epigenetics describes dynamic alterations in a cell
that switch genes on and oﬀ without changes in the DNA
sequence. Epigenetic modiﬁcations are reversible. Examples
of mechanisms that produce such changes are DNA methyl-
ation and histone modiﬁcation, each of which alters gene
expression. Many cellular processes are inﬂuenced by epige-
netic changes, including gene expression, cellular diﬀerentia-
tion, genomic imprinting, and embryogenesis [43]. DNA
methylation is a chemical process that adds a methyl group
to DNA on the 5th position of the pyrimidine ring of cyto-
sine. It is highly speciﬁc and frequently happens in a region
in which a cytosine nucleotide is located next to a guanine
nucleotide that is linked by a phosphate: a so-called CpG
site. A region of several hundred CpG sites is called
CpG island [41, 43–45]. Many human gene promoters
are associated with CpG islands and are usually unmethy-
lated; a few become methylated during cell development or
diﬀerentiation [41, 43]. DNA methylation can inhibit the
binding of transcription factors to the promoter, and con-
sequently, methylation in the promoter region is associated
with silencing of the adjacent gene due to the abrogation
of transcription [43, 46].
DNA methylation plays a crucial role in the develop-
ment of a variety of cancers, including breast cancer [46].
DNA hypomethylation can lead to oncogene activation
and chromosome instability in tumor development [41].
The loss of methylation in CpG-depleted regions, where
CpG-dinucleotides are expected to be methylated, may be
associated with aberrant or inappropriate expression of
some genes that could contribute to neoplastic transforma-
tion, tumorigenesis, or cancer progression [47]. Conversely,
hypermethylation has been shown to inhibit tumor suppres-
sor genes, thereby releasing cells from their normal physio-
logical control [41, 43].
Multiple reports have suggested that determination of the
methylation status of speciﬁc promoter regions can provide
important information for early detection of cancer, deter-
mine prognosis, and predict the response of a cancer patient
to anticancer drugs [46]. In cancer, many tumor suppressor
genes and various other cancer-related genes have been
found to be hypermethylated. Their biological function
includes cell-cycle regulation, apoptosis, DNA repair, cellular
homeostasis, cell adhesion, and cell invasion [43, 45]. Exam-
ples for hypermethylated breast cancer-associated genes are
BRCA1, CCND2 (cyclin D2), ER, PR, CDH1 (E-cadherin),
and many others [43–49]. The ubiquity of such epigenetic
changes in cancer events through DNA methylation has led
to a variety of innovative diagnostic and therapeutic strategies.
The most recent technical advances have demonstrated
the great potential of DNA methylation markers as valuable
tools for decision-making in the treatment of cancer patients
[43, 50]. In breast cancer, DNA methylation has shown
promise as a potential biomarker for early detection, therapy
monitoring, assessment of prognosis, and prediction of ther-
apy response [46]. DNA methylation markers predicting
response to endocrine therapy with tamoxifen in early and
metastatic breast cancer have been described [45, 50, 51].
Furthermore, the DNA methylation status of the ER gene
has been suggested as a marker for treatment response in
breast cancer patients receiving antihormonal therapy [52].
Association between DNA methylation levels and clinico-
pathological parameters was reported, conﬁrming complex
relationships between DNA methylation and TP53 status or
the ER status [43].
There have been only a few studies focusing on the inves-
tigation of the DNA methylation of certain genes in TNBC
tumor tissues. For example, a DNA methylation signature
relevant for TNBC patients was identiﬁed by Stirzaker et al.
exploring Cancer Genome Atlas data [53]. They showed that
TNBC patients with low levels of tumor DNAmethylation in
their gene signature had the best prognosis, and by their gene
methylation signature, TNBC could be separated from non-
TNBC tumors. Hafez et al. observed that p16 (cyclin-depen-
dent kinase inhibitor 2A), a tumor suppressor gene, which
has a central function in the regulation of cell cycle activa-
tion, was frequently hypermethylated in TNBC cases, and
p16 hypermethylation was signiﬁcantly increased in TNBC
compared to non-TNBC [54].
Several studies have focused on the methylation status of
the BRCA1 gene, a key player in breast cancer including
TNBC. TNBC breast cancer cell lines with BRCA1 DNA
methylation were more sensitive to PARP inhibitors when
BRCA1 gene was methylated [55]. TNBC patients with pCR
to adjuvant chemotherapy expressed higher BRCA1methyla-
tion values than nonresponders [56], and the study from Xu
et al. demonstrated an increased 10-year disease-free survival
of 78% in TNBC patients with BRCA1methylation compared
to 55% in patients without BRCA1 methylation [57].
Being aware that DNA methylation is altered in breast
cancer cells compared to normal breast cells and new assays
that determine these changes and thus provide information
about the patient’s response to anti-cancer drugs need to be
introduced into clinical practice in the near future. Although
some genes altered by DNA methylation have been associ-
ated with response to adjuvant therapy in breast cancer
patients in small exploratory studies using laboratory-
developed tests, currently, for breast cancer testing, no
predictive DNA methylation test is commercially available
yet. This is remarkable since, in contrast to RNA and pro-
teins, DNA is a very stable biological material that can be
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extracted from the same archived clinical tissue sample
that is subjected to inspection by the pathologist for routine
malignancy assessment.
6. Pathobiology of PITX2 in Breast Cancer
PITX2 (paired-like homeodomain transcription factor 2,
also known as pituitary homeobox 2) is a transcription fac-
tor, which is involved in the morphogenesis of anterior
structures, such as eyes and teeth. PITX2 is involved in
pituitary-speciﬁc gene regulation and left-right patterning
during embryonic and organogenic development [58, 59].
PITX2 has three diﬀerent isoforms, leading to three diﬀer-
ent proteins (PITX2A, PITX2B, and PITX2C), which diﬀer-
entially regulate transcription of their target genes [60].
Two promoters (P1 and P2) are operational: P2 drives tran-
scription of two mRNA variants, leading to the PITX2A
and B proteins; P1 drives the third transcript variant encod-
ing the C protein [58, 61, 62]. Expression of isoforms 1 and
2 is regulated by the Wnt/β-catenin pathway, and expres-
sion of isoform 3 is regulated by TGF-β family members
[48, 58]. Both the Wnt/β-catenin pathway and the TGF-β
pathway play important roles in carcinogenesis, but the
results from Pillai et al. support the notion that PITX2 plays
a role in mediating invasiveness of cancer cells through the
Wnt/β-catenin pathway [58]. PITX2 functions in the Wnt-
signaling pathway by recruiting and interacting with cyto-
solic β-catenin, the central molecule in the canonical Wnt
pathway. This leads to stabilization of β-catenin, which
then enters the nucleus and associates with transcription
factors leading to transcription of cell cycle regulatory and
proliferation genes (e.g., cyclin D1, c-Myc, and MMP7),
and subsequently enhances cell proliferation [17].
Even today, the role of PITX2 in breast carcinogenesis is
unclear; however, there is a role of PITX2 DNA methylation
for the prognosis of the course of the breast cancer disease.
Nimmrich et al. reported that PITX2 DNA methylation
assessed in breast cancer tissue is a high-risk indicator of dis-
ease recurrence in N0 ER/PR+ patients [48]. Another study,
employing immunohistochemistry for PITX2 determination,
revealed a signiﬁcant association between PITX2 protein and
ER/PR expression, indicating that PITX2 and ER/PR protein
expression may be useful prognostic markers in invasive
breast cancer [63]. Jezkova et al. observed hypermethylation
of PITX2 in about 50% of invasive breast cancers [64]; an
association of PITX2 expression with established parameters
such as ER, PR, and HER2 was described by Rahman et al.
[63]. Further, PITX2 DNA methylation rates were found to
be higher in tumors with elevated ER levels [49]. Jezkova
et al. found that PITX2 DNA methylation status was associ-
ated with high tumor grade and clinical tumor stage of breast
cancer patients [64].
A further breast cancer study (ER/PR+, N0) was con-
ducted by Nimmrich et al. [48]. The authors reported that
PITX2 DNA methylation acts as a statistically independent
prognostic marker for these untreated breast cancer patients,
implying that tumors with a hypermethylated PITX2 status
are more aggressive. In a univariate survival analysis, the
authors did show that PITX2 DNA methylation is associated
with early distant metastases and poor overall survival. In
a multivariate analysis, PITX2 retained its statistical sig-
niﬁcance, together with the established prognostic factors
age, tumor size, and nuclear grade, plus ER/PR [48]. This
study also conﬁrmed that in clinical samples PITX2 DNA
hypermethylation is positively associated with breast cancer
disease progression [45, 48].
Results from the scientiﬁc literature provide further evi-
dence that PITX2 DNA methylation analysis may allow clin-
ically relevant risk assessment in tamoxifen-treated primary
breast cancers [51, 65]. In the study performed by Maier
et al., PITX2 DNAmethylation showed the strongest correla-
tion with metastasis-free survival in N0 ER/PR+, tamoxifen-
treated breast cancer patients, with high PITX2 DNA
methylation representing poor metastasis-free survival [51].
Harbeck et al. could show that PITX2 methylation in N0
ER/PR+, tamoxifen-treated patients added signiﬁcant infor-
mation to the histopathological factors tumor size, histologi-
cal grade, and patient age [65]. Both studies underline that
PITX2 DNA methylation may be a potential biomarker for
predicting outcome in patients with N0 ER/PR+ breast can-
cer patients treated with tamoxifen monotherapy [51, 65].
Furthermore, a strong correlation between PITX2 DNA
methylation and disease recurrence was found: 86% of
patients with low PITX2 DNA methylation were metastasis-
free after 10 years, compared to only 69% with elevated
PITX2 DNA methylation [51]. In survival analyses, PITX2
DNA methylation added statistically signiﬁcant independent
prognostic value to the clinical impact of the established clin-
ical and histomorphological factors.
7. Clinical Implication of PITX2 in High-Risk
Breast Cancer Patients
According to the St. Gallen risk stratiﬁcation panel, breast
cancer patients with >3 aﬀected axillary lymph nodes and
tumor size> 2 cm are classiﬁed high-risk and treated with
chemotherapy; the same applies to TNBC patients.
Anthracycline-based chemotherapy has become the standard
of care for these patients.
7.1. High-Risk Breast Cancer of the Triple-Negative Subtype
(TNBC). In a recent study, PITX2 DNA methylation status
and its clinical impact for TNBC patients were investigated
[66]. PITX2 DNA methylation was determined in primary
tumor tissues obtained from TNBC patients before treatment
with adjuvant anthracycline-based chemotherapy. In this
retrospective study, PITX2 DNA methylation was the only
signiﬁcant factor as assessed by univariate and multivariate
survival analysis; in combination with PITX2 DNA methyla-
tion status; none of the established clinical and histomorpho-
logical parameters (age, histological grade, tumor size, and
lymph node status) showed statistical signiﬁcance for pre-
dicting the rate of disease-free or overall survival [66].
In contrast to the above-cited studies involving PITX2
DNA methylation status in ER/PR+ breast cancer patients,
the results obtained by Absmaier et al. revealed evidence that
for TNBC patients treated with adjuvant anthracycline-
based chemotherapy, a low PITX2 DNA methylation status
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is associated with a decrease in the progression-free inter-
val [66]. Kaplan-Meier analyses demonstrated that a high
PITX2 DNA methylation status is associated with a favor-
able prognosis for both disease-free and overall survivals.
5-year observation rates (disease-free survival) diﬀer signif-
icantly in favor of the high PITX2 DNA methylation group
(Figure 3). For patients who did not receive any chemo-
therapy or who received chemotherapy that was not based
on anthracyclines, this risk group separation was not
apparent. These results indicate that for TNBC patients
treated with adjuvant anthracycline-based chemotherapy,
assessment of the PITX2 DNA methylation status may
serve as a marker that predicts response to anthracycline-
based chemotherapy.
7.2. High-Risk Breast Cancer with >3 Axillary Lymph
Nodes. PITX2 DNA methylation was also analyzed in
high-risk (N+, ER/PR+, and HER2−) breast cancer patients
treated with adjuvant anthracycline-based chemotherapy,
which improved clinical outcome of the patients. In this
study, the authors could show that PITX2 DNA methyla-
tion status signiﬁcantly predicts the outcome of the
patients [44]. The ﬁnding was that PITX2 DNA methyla-
tion status and that of fourteen other methylated genes pre-
dicted clinical outcome in these patients. PITX2 DNA
hypermethylation was associated with a high risk of develop-
ing metastases in this group of patients (Figure 4). In multi-
variate analysis, PITX2 hypermethylation evolved as a
signiﬁcant marker to predict outcome [44], when assessed
together with the parameters age at the time of surgery,
tumor stage, nuclear grade, progesterone receptor status,
and adjuvant endocrine therapy. This study provided addi-
tional strong evidence that PITX2 DNA methylation status
may serve as a useful biomarker in high-risk N+ breast
cancer to predict response to anthracycline-based chemo-
therapy (Figure 4).
Anthracyclines can cause severe side eﬀects; therefore, a
marker which could predict sensitivity to anthracyclines in
high-risk breast cancers would be highly valuable. Several
studies described a positive association of PITX2DNAmeth-
ylation status with aggressiveness of the disease and with
clinical outcome. Summarizing the clinical impact of PITX2
DNA methylation in high-risk breast cancer patients, there
is evidence that PITX2 DNA methylation may serve as a
valuable predictive marker to distinguish between respond-
ing and nonresponding patients (Figure 2).
8. Hypothesis to Explain the Controversial
PITX2 DNA Methylation Status in Predicting
Therapy Response in Breast Cancer Patients
The data above raise the question how we can explain
that hypomethylation of PITX2 predicts nonresponders
in TNBC and hypermethylation of the PITX2 gene pre-
dicts nonresponders in ER+ breast cancer. The canonical
Wnt-signaling pathway is activated in several tumor types
including breast cancer (Figure 5). The major eﬀector of
this pathway is β-catenin, which is stabilized in the cyto-
plasm, translocates to the nucleus, and controls gene
expression [17]. PITX2 and β-catenin pathways upregulate
the ABC transporter system, especially ABCG2, which is also
known as BCRP (breast cancer resistant protein). ABCG2,
which belongs to the family of membrane proteins, possesses
an ATP-binding cassette and transports speciﬁc substrates
actively through cellular membranes. It mediates the eﬄux
of drugs and contributes to multidrug resistance in cancer.
Substrates of ABCG2 include anticancer drugs such as
anthracyclines, topoisomerase inhibitors, tyrosine kinase
inhibitors, and antimetabolites [67].
The increased expression of such transporters on plasma
membranes results in an increased eﬄux and decreased
intracellular accumulation of many anticancer drugs, ulti-
mately leading to multidrug resistance [67]. Several tran-
scription factors regulate ABCG2, including, but not limited
to, the steroid hormone receptors ER/PR and estrogen/pro-
gesterone response elements [67]. In TNBC, low methylation
(hypomethylation) of the PITX2 gene predicts poor disease-
free and/or overall survival in nonresponders to neoadjuvant
chemotherapy [58]. PITX2 regulates the Wnt/β-catenin
pathway [60], and β-catenin is required for the tumorigenic
behavior of TNBC [21]. PITX2 and the β-catenin pathway
upregulate the ABCB1 transporter [68, 69], another eﬄux
transporter of the same gene family involved in multidrug
resistance. ABCB1 is responsible to eﬄux small drugs such
as anthracyclines and therefore mediates chemoresistance
[70]. In summary, hypomethylation of PITX2 may lead to
the activation of the Wnt/β-catenin pathway with subse-
quent upregulation of the ABCG2 or ABCB1 transporter
triggering resistance to chemotherapy.
In high-risk ER+ BC, high PITX2 gene methylation
(hypermethylation) predicts poor disease-free and overall
survival [44, 71]. The Wnt/β-catenin pathway is a positive
regulator of ER in breast cancer. Hypermethylation of PITX2
results in silencing of the Wnt/β-catenin pathway with
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Figure 3: 5-year disease-free survival rate analysis of TNBC patients
treated with anthracycline-based adjuvant chemotherapy. At 5 years
of follow up, the TNBC patients were grouped according to their
PITX2 DNA methylation value with a cut-oﬀ of 6.35 percent
methylation ratio (PMR). Low PITX2 DNA methylation status
(n = 18) shows a poor disease-free survival rate at 5 years (35.6%);
high PITX2 DNA methylation status (n = 38) is associated at 5-
year observation time with favorable disease-free survival (83.5%).
(p values: log-rank test, p = 0 006; Wilcoxon test, p = 0 003) [66].
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subsequent downregulation of estrogen and its receptor
ER, causing estrogen deprivation/independency in ER-pos-
itive cancer cells [72]. The ABCG2 transporter is downreg-
ulated by estrogen [73]; that is, estrogen deprivation leads
to increased ABCG2 expression. If PITX2 is hypermethy-
lated, the Wnt/β-catenin pathway is silenced and subse-
quent ER downregulation leads to (a) overexpression of
the ABCG2 transporter and thereby to anthracycline resis-
tance and (b) tamoxifen (ER antagonist) resistance because
of estrogen independency.
9. Prospects and Perspectives for Clinical
Use of PITX2 DNA Methylation Status in
Cancer Patient Management
Determination of the DNA methylation status of certain
genes reﬂects an emerging ﬁeld of cancer biomarkers. Prom-
ising recent results highlight its potential for early
detection, assessment of prognosis, prediction of therapy
response, and therapy monitoring in various cancer dis-
eases, which can be performed on tissue samples and on
cell-free-circulating DNA in body ﬂuids [88]. For optimum
management of cancer patients, however, accurate and
highly signiﬁcant prognostic and predictive factors are of
eminent medical need. In particular, predictive cancer bio-
markers are needed to determine the right systemic therapy
for patients aﬄicted with any of the heterogeneous high-
risk breast cancer subgroups, characterized by varying out-
comes, since certain systemic adjuvant therapies may be
beneﬁcial for a subgroup of patients only, while others will
suﬀer from potentially toxic and unnecessary therapy-related
side eﬀects [41].
In order to be of clinical use, a cancer biomarker
should be detectable in biological samples readily available
without interrupting the routine clinical workﬂow. A suit-
able assay for routine diagnostics must be robust, simple
to use, standardized, evaluated in external quality assurance
Chemoresistance
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Wnt/훽-catenin
silencing
PITX2
DNA hypermethylation
Conversion to
estrogen
independency
Wnt/훽-catenin
activation
Tamoxifen resistance 
TNBC
ER + BC ABCG2
Upregulation
Upregulation through
estrogen abrogation
Figure 5: Predictive signiﬁcance of PITX2 gene methylation in high-risk breast cancer patients. TNBC and ER+ BC are two biologically
diﬀerent high-risk breast cancer entities. Yet, for both, the PITX2 DNA methylation status has been shown to predict response or failure
to anthracycline-based chemotherapy [44, 66]. The controversial results of the favorable clinical signiﬁcance of PITX2 gene
hypermethylation in TNBC patients versus PITX2 gene hypomethylation in ER+ BC patients are outlined. The hypothesis presented is
based on published evidence; other, so far unknown, mechanisms may be involved as well. ER+ BC= estrogen receptor-positive breast cancer.
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Figure 4: Kaplan-Meier survival curves demonstrating metastasis-free survival probability of high-risk breast cancer patients (n = 133). ER+
breast cancer patients with >3 lymph nodes aﬀected were treated with anthracycline-based chemotherapy plus endocrine therapy. Patients
were grouped according to their PITX2 DNA methylation score. PITX2 high gene methylation (quartile 4) predicts poor survival and
PITX2 low gene methylation (quartiles 1–3) favorable survival (data reanalyzed from [44]).
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schemes, and made available at aﬀordable costs. Evaluation
of such a marker should adhere to the REMARK/BRISQ cri-
teria [79, 80]. In this respect, assessment of the PITX2 DNA
methylation status in primary tumor tissues has demon-
strated its prognostic and predictive value for several cancer
indications (Table 5). A cancer patient’s PITX2DNAmethyl-
ation status can be determined reliably by real-time PCR
technology employing DNA extracted from formalin-ﬁxed,
paraﬃn-embedded (FFPE) tissue [46]. For this purpose, a
validated PITX2 test kit is required to expedite its clinical
utility. Once these requirements are met, determination of
PITX2 DNA methylation status might become an important
measure to aid clinicians in advising the optimal cancer
therapy to their patients.
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